Long-Term Outcomes of Ublituximab Treatment in Multiple Sclerosis: 5-Year ULTIMATE OLE Data

Overview

Ublituximab, a glycoengineered anti-CD20 monoclonal antibody with enhanced ADCC, demonstrated sustained efficacy and safety over 5 years in patients with relapsing multiple sclerosis (RMS) in the ULTIMATE I and II open-label extension (OLE) trials. Long-term treatment resulted in low annualized relapse rates and stable or improved disability measures, supporting its role as an effective disease-modifying therapy.

Background

Anti-CD20 monoclonal antibodies have transformed the treatment landscape of multiple sclerosis by depleting B cells through mechanisms including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytolysis. Ublituximab is a novel anti-CD20 mAb engineered for enhanced ADCC via low fucose content in its Fc region, resulting in higher Fcγ receptor affinity and greater B-cell depletion compared to other therapies. The ULTIMATE I and II phase 3 trials showed superior efficacy of ublituximab versus teriflunomide over 2 years, and the ongoing OLE study evaluates its long-term safety and efficacy in RMS.

Data Highlights

Key Findings

• Ublituximab showed sustained low annualized relapse rates over 5 years in RMS patients.
• Participants experienced low rates of 24-week confirmed disability progression, indicating long-term disease stability.
• Some patients demonstrated 24-week confirmed disability improvement, reflecting potential neurological recovery.
• Neurological function assessed by MSFC remained stable or improved annually during long-term treatment.
• Ublituximab infusions were well tolerated with shorter infusion times compared to other anti-CD20 therapies.
• The study was conducted across multiple international sites with rigorous ethical oversight and adherence to clinical trial standards.

Clinical Implications

Ublituximab offers a potent and durable treatment option for relapsing MS with the convenience of shorter infusion times and a favorable safety profile. Its enhanced ADCC mechanism may contribute to sustained disease control and potential disability improvement. Clinicians can consider ublituximab as a long-term therapy to reduce relapse rates and stabilize or improve neurological function in RMS patients.

Conclusion

The 5-year data from the ULTIMATE OLE trials confirm that ublituximab provides sustained efficacy and safety in relapsing multiple sclerosis, supporting its use as a long-term disease-modifying therapy. Enhanced ADCC and convenient administration make it a valuable option in MS management.

References

1. ULTIMATE I and II Trials -- Ublituximab in Relapsing MS
2. Anti-CD20 mAbs Mechanisms and Clinical Use in MS